HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Abstract
The ruthenium-based drug NAMI-A, characterised by its selectivity against solid tumour metastases, promotes TGF-β1-dependent fibrosis and the reduction of the release of MMPs in the primary tumour. The aim of the study was to examine the interaction of NAMI-A with TGF-β1 in the process of metastasis formation. NAMI-A (1) affects the secretion of TGF-β1 in metastatic MDA-MB-231 cells rather than in non-tumorigenic HBL-100 cells, (2) prevails over TGF-β1 with regard to the invasive capacity of the treated cells, and (3) contrasts integrin-dependent migration stimulated by TGF-β1. It, thus, appears that the effects of NAMI-A on cell invasion and migration are best summarised as an interference with TGF-β1 and a reduction of its activity in these events. At a molecular level, the similar activity of NAMI-A and TGF-β1 on RhoA GTPase supports its interaction with cell surface integrins while TGF-β1 can activate it by interaction with its TGFβR receptor. The inhibition of TGF-β1-induced migration of MDA-MB-231 cells by NAMI-A cannot simply be attributed to a modulation of the Smad2 and p38MAPK pathways. In conclusion, the effects of NAMI-A on the biological role of TGF-β1 in cancer metastasis are insufficient to attribute the responsibility for the anti-metastatic activity of the ruthenium-based drug to this target alone.
AuthorsL Brescacin, A Masi, G Sava, A Bergamo
JournalJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry (J Biol Inorg Chem) Vol. 20 Issue 7 Pg. 1163-73 (Oct 2015) ISSN: 1432-1327 [Electronic] Germany
PMID26369538 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Organometallic Compounds
  • Ruthenium Compounds
  • Transforming Growth Factor beta1
  • imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III)
  • Ruthenium
  • Dimethyl Sulfoxide
Topics
  • Antineoplastic Agents (chemistry, pharmacology)
  • Cell Adhesion (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Dimethyl Sulfoxide (analogs & derivatives, chemistry, pharmacokinetics, pharmacology)
  • Humans
  • Molecular Structure
  • Neoplasm Metastasis (drug therapy)
  • Neoplasms (drug therapy, physiopathology)
  • Organometallic Compounds (chemistry, pharmacokinetics, pharmacology)
  • Ruthenium (chemistry, pharmacology)
  • Ruthenium Compounds
  • Transforming Growth Factor beta1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: